P-004 - 18F-DCFPYL PET/CT IN RADIOTHERAPY PLANNING FOR SALVAGE RADIOTHERAPY AFTER PROSTATECTOMY
P-013 - ACTIVE BREATHING COORDINATOR VERSUS DAMPENING IN BONE SBRT
P-019 - ADJUVANT RADIATION THERAPY AFTER RADICAL PROSTATECTOMY
P-020 - ADJUVANT RADIOTHERAPY IN LOCAL ADVANCE PENILE SQUAMOUS CELL CARCINOMA
P-025 - ANDROGEN RECEPTOR TARGETED THERAPY IN PROSTATE CANCER: OUR EXPERIENCE
P-026 - APALUTAMIDA EN PACIENTES CON CÁNCER DE PRÓSTATA METASTÁSICO HORMONOSENSIBLE
P-027 - APALUTAMIDE-TDA+RT/SBRT. NEW STANDARD OF CARE IN MHSPC OLIGOMETASTATIC?
P-030 - ASSESSING RADIATION DOSE FOR POSTOPERATIVE RADIOTHERAPY IN PROSTATE CANCER: REAL-WORLD-DATA
P-063 - CPRC M0: AN INSTITUTIONAL EXPERIENCE
P-067 - DAROL STUDY IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER
P-068 - DAROLUTAMIDE IN NMCRPC PATIENTS WITH AND WITHOUT PRIOR LOCAL THERAPY
P-075 - DIFFERENCES IN THE APALUTAMIDE-RESPONSE ACCORDING TO THE LOCATION OF METASTASIS
P-077 - DOES ADVANCED IMAGING MODIFY RADIOTHERAPY IN EXCLUSIVE NODAL-OLIGORECURRENCE AFTER SURGERY?
P-083 - DOSIMETRIC PARAMETERS IN PATIENTS WITH ADRENOCORTICAL CARCINOMA TREATED WITH HELICAL-TOMOTHERAPY.
P-087 - EARLY EVALUATION OF PSA KINETICS IN M-HSPC TREATED WITH APALUTAMIDE
P-089 - EARLY EXPERIENCE WITH PSMA/PET IN BIOCHEMICAL RECURRENCE OF PROSTATE CANCER
P-093 - EFFICACY AND TOXICITY OF APALUTAMIDE IN METASTATIC-PROSTATE CANCER: OUR EXPERIENCE
P-110 - EXPERIENCE WITH APALUTAMIDE FOR PROSTATE CANCER IN A SINGLE INSTITUTION
P-111 - EXPERIENCE WITH APALUTAMIDE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
P-116 - EXTERNAL BEAM RADIOTHERAPY FOR LOCALLY ADVANCED PROSTATE CANCER
P-121 - EXTREMELY HYPO-FRACTIONATED PROSTATE CANCER WITH HYDROGEL BARRIER